Xylitol Clinical Studies for Prevention - Xylitol Frequency Study (Gum 2)

ISRCTN ISRCTN43479664
DOI https://doi.org/10.1186/ISRCTN43479664
Protocol serial number U54 DE14254
Sponsor University of Washington (USA)
Funder National Institute of Dental and Cranio-facial Research (NIDCR) (USA) - ref: U54 DE14254
Submission date
16/11/2005
Registration date
22/11/2005
Last edited
13/10/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Oral Health
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Peter Milgrom
Scientific

Dental Public Health Sciences
1959 NE Pacific Street
Rm B-509
Box 357475
Seattle, Washington
98195
United States of America

Phone +1 206 543 4043
Email dfrc@u.washington.edu

Study information

Primary study designInterventional
Study designRandomised controlled trial
Secondary study designRandomised controlled trial
Scientific title
Study acronymGum 2
Study objectivesIncreasing reduction in mutans streptococci level in plaque and saliva to increasing frequency of xylitol use at the same total daily dose.
Ethics approval(s)University of Washington Internal Review Board - Application#: 04-2024-B 01. Approved 17/06/2004.
Health condition(s) or problem(s) studiedDental caries
Intervention4 group design. Control (sorbitol gum) group and 3 xylitol gum groups who consumed 10.32 g xylitol per day. All 4 groups chewed 12 pellets of gum per day. Xylitol groups evenly divided the 12 gums into 2, 3, or 4 chewing frequency. Controls chewed sorbitol gums 4 times per day.
Intervention typeDrug
PhaseNot Specified
Drug / device / biological / vaccine name(s)Xylitol
Primary outcome measure(s)

Reduction in mutans streptococci level in plaque and saliva

Key secondary outcome measure(s)

Not provided at time of registration

Completion date01/03/2005

Eligibility

Participant type(s)Patient
Age groupAdult
SexAll
Target sample size at registration132
Key inclusion criteriaAdult, male & female, with screening plaque mutans streptococci level greater than 10,000 CFU/ml
Key exclusion criteria1. Gastro-intestinal diseases/problems
2. Phenylalanine intolerant
Date of first enrolment01/04/2004
Date of final enrolment01/03/2005

Locations

Countries of recruitment

  • United States of America

Study participating centre

Dental Public Health Sciences
Seattle, Washington
98195
United States of America

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 24/03/2006 Yes No